- Home
- WLAC vs BDTX Comparison
WLAC vs BDTX Comparison
Compare WLAC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.52
Company Overview
Basic Information| Metric | WLAC | BDTX |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 220.3M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WLAC | BDTX |
|---|---|---|
| Price | $12.18 | $2.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $17.00 | $10.60 |
| AVG Volume (30 Days) | 202.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $844.52 | ★ $6.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.80 | $1.20 |
| 52 Week High | $15.19 | $4.94 |
Technical Indicators
Market Signals| Indicator | WLAC | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 27.63 |
| Support Level | $11.21 | $2.61 |
| Resistance Level | $12.35 | $2.72 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 84.65 | 18.30 |
Price Performance
Historical Comparison WLAC
BDTX
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.